.webp)
Italian Pharma Chiesi's acquisition of KalVista signals strategic expansion into rare disease immunology markets globally.
Chiesi, an Italian Pharma company based in Italy, has reached an agreement to acquire KalVista Pharmaceuticals from Massachusetts in an all cash transaction for approximately $1.9 billion; making this acquisition the largest for Chiesi to date. As part of the agreement, Chiesi will pay KalVista $27.00 per share and the transaction will close in Q3 of 2026 assuming customary closing conditions are met.
Chiesi’s acquisition of KalVista increases its existing rare disease portfolio by adding EKTERLY® (sebetralstat), a revolutionary on-demand oral treatment for hereditary angioedema ("HAE"), which is a rare genetic disorder that is characterized by severe swelling episodes. Sebetralstat is the only oral on-demand therapy available for patients age 12 and older that treats HAE. This health medication addresses a significant gap for patients with HAE by providing an accessible treatment option.
KalVista has obtained regulatory approval for sebetralstat in all major jurisdictions: the United States, U.K., E.E.A. and Japan. Sebetralstat had strong commercial launch success in the U.S. market from July 2025 to July 2022, where it generated sales of $49 million during the first year after being launched, and indicating substantial commercial traction.
The Chiesi leadership team underlined the strategic fit of this acquisition, with Jean-Marc Bellemin (CFO and interim Group CEO of Chiesi as of May 15, 2026) stating that this deal “supports our strategy to accelerate our impact in the rare disease space through the combination of science, innovation and expertise.” Executive Vice President of Chiesi Global Rare Diseases Giacomo Chiesi said the acquisition demonstrates the company’s commitment to the hereditary angioedema patient community and its ongoing focus on expanding treatment options for patients who do not currently have adequate medical care available.
The all-cash transaction also provides a significant premium to KalVista shareholders. CEO Ben Palleiko believes that Chiesi will be successful in increasing global access to sebetralstat, highlighting Chiesi’s strong existing infrastructure, as well as the company’s extended history of commitment to patients with rare diseases.
Business Honor is of the view that Chiesi's KalVista acquisition represents a strategic pivot toward rare disease market dominance.
.webp)
